No clear answer
DHODH inhibition (pyrimidine synthesis): slow disability worsening in relapsing MS
relapsing MS · DHODH inhibition (pyrimidine synthesis)
Trials have tried this, but none was a controlled phase 2 or 3 trial with a readable result.
- Trials
- 2
- Running now
- 0
- Controlled phase 2/3 trials
- 0
- People in controlled trials
- 0
How the verdict was reached
No result yet
| Trial | Phase | Participants | Started | Result | Counted |
|---|---|---|---|---|---|
| TENERE | Phase 3 | 324 | 2009 | Missed its main goal | Not counted: did not beat an active medicine (interferon beta-1a), which says nothing about placebo |
| TREAT-MS | Not a drug-phase study | 900 | 2018 | Paper found, not read | Not counted: not randomised |
Counted: 0. Will count later: 0. Not counted: 2.
Lab evidence
Lab studies in animals or cells. Results in animals often do not hold in people, and these studies never change the status of an idea.
Loading lab studies…
Loading reviews and guidelines…
History
- Oct 2026First listed as No clear answer
Related hypotheses
Assembled by software from public sources.